P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2

• M. L. Wang,
• J. Munoz,
• A. Goy,
• F. L. Locke,
• C. A. Jacobson,
• B. T. Hill,
• J. M. Timmerman,
• H. Holmes,
• I. W. Flinn,
• D. B. Miklos,
• J. M. Pagel,
• M. J. Kersten,
• R. Houot,
• A. Beitinjaneh,
• W. Peng,
• X. Fang,
• R. R. Shen,
• R. Siddiqi,
• I. Kloos,
• P. M. Reagan

Affiliations

M. L. Wang

1 The University of Texas MD Anderson Cancer Center, Houston, TX

J. Munoz

2 Banner MD Anderson Cancer Center, Gilbert, AZ

A. Goy

3 John Theurer Cancer Center, Hackensack University, Hackensack, NJ

F. L. Locke

4 Moffitt Cancer Center, Tampa, FL

C. A. Jacobson

5 Dana-Farber Cancer Institute, Boston, MA

B. T. Hill

6 Cleveland Clinic Foundation, Cleveland, OH

J. M. Timmerman

7 David Geffen School of Medicine at UCLA, Los Angeles, CA

H. Holmes

8 Texas Oncology, Dallas, TX

I. W. Flinn

9 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

D. B. Miklos

10 Stanford University School of Medicine, Stanford, CA

J. M. Pagel

11 Swedish Cancer Institute, Seattle, WA, United States of America

M. J. Kersten

12 Amsterdam UMC, University of Amsterdam, Amsterdam, Cancer Center Amsterdam, The Netherlands, on behalf of HOVON/LLPC, Amsterdam, Netherlands

R. Houot

13 CHU Rennes, Université Rennes, INSERM & EFS, Renne, France

A. Beitinjaneh

14 University of Miami, Miami, FL

W. Peng

15 Kite, a Gilead Company, Santa Monica, CA

X. Fang

15 Kite, a Gilead Company, Santa Monica, CA

R. R. Shen

15 Kite, a Gilead Company, Santa Monica, CA

R. Siddiqi

15 Kite, a Gilead Company, Santa Monica, CA

I. Kloos

15 Kite, a Gilead Company, Santa Monica, CA

P. M. Reagan

16 University of Rochester Medical Center, Rochester, NY, United States of America